<DOC>
	<DOCNO>NCT02752035</DOCNO>
	<brief_summary>The purpose study determine efficacy superiority ASP2215 and/or ASP2215 plus azacitidine versus azacitidine measure overall survival ( OS ) event-free survival .</brief_summary>
	<brief_title>A Study ASP2215 ( Gilteritinib ) , Combination ASP2215 Plus Azacitidine Azacitidine Alone Treatment Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase ( FLT3 ) Mutation Patients Not Eligible Intensive Induction Chemotherapy</brief_title>
	<detailed_description>Subjects consider adult accord local regulation time obtain informed consent may participate study . Safety Cohort Prior initiation randomize trial , 8 12 subject enrol evaluate safety tolerability ASP2215 give azacitidine therapy study population . Randomized Trial Approximately 528 subject randomize 1:1:1 ratio receive ASP2215 ( Arm A ) , ASP2215 plus azacitidine ( Arm AC ) azacitidine ( Arm C ) . Subjects enter screen period 14 day prior start treatment . Subjects administer treatment 28-day cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Subject consider adult accord local regulation time obtain informed consent . Subject diagnosis previouslyuntreated AML accord World Health Organization ( WHO ) classification [ Swerdlow et al , 2008 ] determine pathology review treat institution . Subject positive FLT3 mutation ( internal tandem duplication [ ITD ] tyrosine kinase domain [ TKD ] [ D835/I836 ] mutation ) bone marrow whole blood determine central laboratory . Subject ineligible intensive induction chemotherapy meeting least 1 follow criterion : 1 . Subject ≥ 75 year age . 2 . Subject follow comorbidities : Congestive heart failure ( New York Heart Association { NYHA } class ≤ 3 ) ejection fraction ( Ef ) ≤ 50 % ; Creatinine &gt; 2 mg/dL ( 177 µmol/L ) , dialysis prior renal transplant ; ECOG performance status ≥ 3 ; Prior current malignancy require concurrent treatment ; Subject receive cumulative anthracycline dose 400 mg/m2 . Subject must meet follow criterion indicate clinical laboratory test : Serum AST ALT ≤ 2.5 x Institutional upper limit normal ( ULN ) Serum total bilirubin ≤ 1.5 x Institutional ULN Serum potassium ≥ Institutional low limit normal ( LLN ) Serum magnesium ≥ Institutional LLN Subject suitable oral administration study drug . Female subject must either : Be nonchildbearing potential : Postmenopausal ( define least 1 year without menses ) prior screen , Documented surgically sterile status posthysterectomy ( least 1 month prior screen ) Or , childbearing potential , Agree try become pregnant study 60 day final study drug administration And negative urine serum pregnancy test screening And , heterosexually active , agree consistently use 2 form effective contraception per locally accept standard , 1 must barrier method , start screen throughout study period 60 day final study drug administration . Female subject must agree breastfeed start screen throughout study period , 60 day final study drug administration . Female subject must donate ovum start screen throughout study period , 60 day final study drug administration . Male subject female partner childbearing potential must use 2 form effective contraception per locally accept standard , 1 must barrier method , start screening continue throughout study period , 120 day final study drug administration . Male subject must donate sperm start screen throughout study period 120 day final study drug administration . Subject agree participate another interventional study treatment . Subject diagnose acute promyelocytic leukemia ( APL ) . Subject BCRABLpositive leukemia ( chronic myelogenous leukemia blast crisis ) . Subject receive previous therapy AML , exception following : Emergency leukapheresis Hydroxyurea ≤ 14 day Preemptive treatment retinoic acid prior exclusion APL ≤ 7 day Growth factor cytokine support Steroids treatment hypersensitivity transfusion reaction Subject clinically active central nervous system leukemia . Subject diagnose another malignancy require concurrent treatment hepatic malignancy regardless need treatment . Subject clinically significant coagulation abnormality unless secondary AML . Subject major surgery within 4 week prior first study dose . Subject radiation therapy within 4 week prior first study dose . Subject require treatment concomitant drug strong inducer cytochrome P450 CYP3A . Subject require treatment concomitant drug strong inhibitor inducer Pgp exception drug consider absolutely essential care subject . Subject require treatment concomitant drug target serotonin 5HT1R 5HT2BR sigma nonspecific receptor exception drug consider absolutely essential care subject . Subject congestive heart failure classify New York Heart Association Class IV . Subject mean Fridericiacorrected QT interval ( QTcF ) &gt; 450 m screen base central reading . Subject history Long QT Syndrome screening . Subject know pulmonary disease diffusion capacity lung carbon monoxide ( DLCO ) ≤ 65 % , forced expiratory volume first second ( FEV1 ) ≤ 65 % , dyspnea rest require oxygen pleural neoplasm . Subject active uncontrolled infection . If infection present , patient must receive definitive therapy sign progress infection . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Subject know human immunodeficiency virus infection . Subject active hepatitis B C active hepatic disorder . Subject condition make subject unsuitable study participation , include contraindication azacitidine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>ASP2215</keyword>
	<keyword>Newly Diagnosed AML</keyword>
	<keyword>Acute Myeloid Leukemia ( AML )</keyword>
	<keyword>FLT3</keyword>
</DOC>